Stock XLO XILIO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Xilio Therapeutics, Inc.

Equities

XLO

US98422T1007

Market Closed - Nasdaq
Other stock markets
 21:00:00 10/05/2024 BST 		5-day change 1st Jan Change
1.18 USD -6.35% Intraday chart for Xilio Therapeutics, Inc. 0.00% +114.55%
04-19 Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says MT
04-01 Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
GL
Xilio Therapeutics : Corporate Update Call
PU
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
GL
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
GL
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
AQ
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
GL
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
AQ
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
GL
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
AQ
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
GL
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
AQ
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
GL
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
GL
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
AQ
Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
GL
Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
AQ
Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023
AQ
Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting
GL
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's 38th Annual Meeting
AQ
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XLO Stock
  4. News Xilio Therapeutics, Inc.
  5. Press Releases